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Abstract
Background: Combination treatment is increasingly used to fight infections caused by bacteria resistant to two
or more antimicrobials. While multiple studies have evaluated treatment strategies to minimize the emergence of
resistant strains for single antimicrobial treatment, fewer studies have considered combination treatments.
The current study modeled bacterial growth in the intestine of pigs after intramuscular combination treatment
(i.e. using two antibiotics simultaneously) and sequential treatments (i.e. alternating between two antibiotics) in
order to identify the factors that favor the sensitive fraction of the commensal flora.
Growth parameters for competing bacterial strains were estimated from the combined in vitro pharmacodynamic
effect of two antimicrobials using the relationship between concentration and net bacterial growth rate. Predictions
of in vivo bacterial growth were generated by a mathematical model of the competitive growth of multiple strains
of Escherichia coli.
Results: Simulation studies showed that sequential use of tetracycline and ampicillin reduced the level of double
resistance, when compared to the combination treatment. The effect of the cycling frequency (how frequently
antibiotics are alternated in a sequential treatment) of the two drugs was dependent upon the order in which the
two drugs were used.
Conclusion: Sequential treatment was more effective in preventing the growth of resistant strains when compared
to the combination treatment. The cycling frequency did not play a role in suppressing the growth of resistant strains,
but the specific order of the two antimicrobials did. Predictions made from the study could be used to redesign
multidrug treatment strategies not only for intramuscular treatment in pigs, but also for other dosing routes.
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Background
Use of antimicrobials is often essential in modern live-
stock production in order to ensure a sufficient level of
animal health and welfare, yet both animal and public
health concerns stress the importance of treatment pro-
tocols that minimize the emergence of resistant bacteria.
Concern over public health is linked to the emergence
of resistance in zoonotic bacteria as well as in com-
mensal bacteria, which may transmit resistance genes to
bacteria in the human gut through the food chain [1].
In 2012, the Danish surveillance scheme on antimicro-
bial resistance (DANMAP) showed that 32 % of the
Escherichia coli isolates from pigs were multi-resistant.
The majority of these (78 %) were co-resistant to ampi-
cillin, sulfonamide and streptomycin, and more than half
of these (55 %) were also resistant to tetracycline [2]. In
order to reduce the level of multi-resistant strains, treat-
ment protocols based on multiple drugs are possible [3],
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and multidrug therapy has increasingly been used world-
wide to fight infections caused by bacteria resistant to
more than one antimicrobials [4–6].
Careful investigation of treatment strategies in multi-
drug treatment is required in order to evaluate the effect
on the commensal flora, as the outcome may depend on
cycling strategy [3], susceptibility levels of bacteria [7],
and the nature of interaction between the antimicrobials
[8]. These interactions are generally classified as synergistic,
antagonistic or additive [9]. While antagonistic effects (i.e.
the combined treatment efficacy of two drugs is less than
the effect of the individual treatments) is unwanted from a
treatment point of view, studies with doxycycline (an im-
portant tetracycline drug used in both animal and human
medicine) have shown that combination treatment with an-
tagonistic drugs (ciprofloxacin in low concentrations)
favored sensitive E. coli over tetracycline resistant E. coli in
competition experiments [8]. The aim of the current study
was to evaluate this observation with another typical drug
class that is antagonistic to tetracycline (β-lactams) and to
elucidate whether it was dependent upon the mode of
treatment (sequential versus combined treatment). The
study by Chati et al, [8] was conducted as a competition
assay between two isogenic strains, though in the intestine
a much more complex competition between many strains
occurs. For example, a recent study showed that nursery
pigs in intensive pig production in Denmark may harbor
many different E. coli strains [10]. Therefore, we extended a
growth model that we previously developed to study the
growth dynamics of multiple E. coli strains in a pig follow-
ing intramuscular (IM) tetracycline treatment [11] to
include combination treatment with ampicillin.
Methods
In vitro growth of E. coli strains under a combination of
drugs
Growth curves for the combined effect of tetracycline and
ampicillin on ten selected E. coli strains were performed
using the automated microbiology growth curve analysis
system BioScreen C™ (Oye Growth Curves Ab Ltd, Finland)
Additional file 1: Figure S1. These ten strains were selected
among the fifty E. coli strains in order to obtain all possible
phenotype combinations and respective resistance levels.
Where, fifty E. coli strains were randomly selected among
160 porcine indicator E. coli isolates from the Danish Inte-
grated Antimicrobial Resistance Monitoring and Research
Program (DANMAP) in 2010 [12]. The 50 isolates were
subcultured, and the susceptibility of strains to tetracycline
and ampicillin was tested using a broth microdilution sus-
ceptibility test, following the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines [13]. Results on
tetracycline susceptibility have previously been reported
[11]. A cut-off value of 8 μg/ml between susceptible and re-
sistant E. coli strains for both tetracycline and ampicillin
was adopted from DANMAP 2010. The ten selected strains
were divided into the four groups, comprising of strains re-
sistant to tetracycline only (RTSA), resistant to ampicillin
only (STRA), resistant to both (RTRA) and susceptible to
both (STSA) with a total of three, two, one and four strains,
respectively (Table 1). Four static concentrations of each
antimicrobial, (0, 0.25, 0.5, 16) μg/ml for tetracycline, and
(0, 1, 4, 16) μg/ml for ampicillin, were used in a four-by-
four array. All isolates were additionally grown in MH-2
media without antibiotics. The BioScreen was set to 18 h
incubation at 37 °C with continuous (250 rpm) shaking,
and optical density (OD) at 600 nm measured every 5 min.
All experiments were performed in biological triplicate.
Growth rate estimation
The BioScreen raw data were extracted in Microsoft Excel.
OD values of blank samples were subtracted from sample
OD values at the respective time points before the data
were analyzed using R (version 3.0.1 for Windows) [14].
The effect of combined antimicrobial concentrations on
the growth of E. coli was assessed from the net growth
rate (μ) of the strains with 16 different combinations. As a
Table 1 Estimated growth parameters and prior growth parameters of ten E. coli strains used in the model for competitive growth
Strain MIC-tet μg/ml MIC-amp μg/ml Combination Parameter Coefficients Priors
αmax EC50tet γtet EC50amp γamp EC50tet γtet EC50amp γamp
A 2.00 1.00 STSA 1.93 1.14 8.35 0.81 2.05 1.14 8.35 0.67 1.92
B 128 4.00 RTSA 1.93 74.03 11.24 5.21 7.03 74.03 11.24 2.53 5.00
C 0.50 1024 STRA 1.81 0.24 1.35 440 5.14 0.15 1.87 440.7 5.14
D 512 1024 RTRA 1.77 187 3.99 400 5.00 186.9 3.99 400 5.00
E 64 8.00 RTSA 2.03 67.5 8.23 4.95 4.84 67.46 8.23 2.85 3.96
F 0.50 4.00 STSA 2.05 0.32 2.42 4.70 5.03 0.23 2.80 2.33 4.00
G 0.50 8.00 STSA 1.93 0.24 1.73 3.59 4.43 0.18 2.24 3.62 4.42
H 16 2.00 RTSA 1.73 9.24 13.95 1.33 1.53 9.24 13.95 1.29 5.00
I 0.50 256 STRA 1.84 0.20 1.26 151.5 5.00 0.14 1.72 151.5 5.00
J 0.25 2.00 STSA 1.76 0.12 1.24 0.46 2.64 0.11 1.83 0.64 2.32
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linear relationship between colony forming units (CFU)
and OD is only valid for low cell concentration and this
relation becomes unreliable above a certain critical value
[15], an OD of 0.1 was taken as a maximum reliable value
in this study. This value was used as the threshold, and
therefore only the exponential growth part of growth
curves below this cut-off was used for the model fit. The
following model equation was used:
Y t ¼ θeμt þ βþ εt ð1Þ
with the parameters Yt: the OD value, θ: the initial OD
value at time zero, μ: the growth rate, β: an offset vari-
able for the adjustment of θ, andεt: a normal error with
mean zero and constant varianceσ2; i.e., εt =N(0, σ
2).
Growth rates for the ten E. coli strains at each combin-
ation were estimated by fitting the model (equation 1) to
growth curves over 18 h using a nonlinear least square
algorithm nls() function of the R software [14].
Estimation of growth parameters and evaluation of drug
interaction
The relationship between antimicrobial concentrations
and net bacterial growth rates under combined concentra-
tions of tetracycline and ampicillin was analyzed using:
α ca; ; cbð Þ ¼ αmaxð1− ca
γa
EC50a
γa þ caγa
Þ
 ð1− cb
γb
EC50b
γb þ cbγb
Þ ð2Þ
Whereα(ca, cb): the net bacterial growth rate with the com-
bination of tetracycline concentrationcaand ampicillin con-
centrationcb,αmax: the bacterial growth rate in the absence
of both drugs, EC50: the concentration at which the drug
effect is reduced to 50 %, and γ: the Hill coefficient, which
is the measure of the steepness of the sigmoid relationship
between concentration c and the growth rate at concentra-
tion c. The subscript a refers to tetracycline, and b refers to
ampicillin, inEC50, γ and c. We had a total of five parame-
ters to estimate for each strain (αmax, EC50a, EC50b, γa, γb).
Growth rates in triplicates derived from the exponential
growth model (equation 1) were plotted against the con-
centration ranges of both tetracycline and ampicillin (Fig. 1)
and fitted to the model (equation 2) for each of the ten E.
coli strains, using a nonlinear minimizing routine nlminb()
of software R [14]. Strains with a minimum inhibitory
concentration (MIC) value greater than the concentration
ranges of the drugs used for in vitro growth curves did not
show any decrease in growth rates (Fig. 1b, d). In such
cases, we did not have any pharmacodynamic information,
and a prior information term
X
ð p−pprior
pprior
Þ2 (from previ-
ously estimated growth parameters of these strains for
tetracycline [11] and ampicillin treatment (Ahmad A,
Zachariasen C, Graesboll K, Christiansen LE, Toft N, Mat-
thews L, et al. Modeling the growth dynamics of mul-
tiple Escherichia coli strains in the pig intestine following
intramuscular ampicillin treatment. submitted) was added
to the residual sum of squares of the model equation for all
parameters except for αmax in order to set up a function for
optimization of the non-linear relation (equation 2). Inclu-
sion of this term insured the convergence of the function,
even in the absence of sufficient information in a relation-
ship of growth and drug concentrations. Outliers from trip-
licates at each combined concentration were removed
based on set criteria (e.g. if the maximum absolute residual
value from model fit is greater than the absolute residual
difference between the other two replicates) before the final
fit. The interaction of two drugs was analyzed using the re-
sidual structure of the fitted model.
In vivo pharmacokinetics
Data for the changing plasma concentrations following IM
treatment of tetracycline and ampicillin in pigs were
obtained from literature [16, 17]. Data were fitted to a two-
compartmental model to estimate absorption, distribution
and elimination rates for each of two drugs (data not
shown). Based on these rates, plasma concentration profiles
of tetracycline and ampicillin were generated and used
simultaneously and sequentially. The treatment duration
was set to a maximum of 6 days.
Mathematical model
The model previously developed to describe the growth
of multiple strains of E. coli following IM treatment with
tetracycline [18] was extended to include the growth of
ten E. coli strains in a pig, following multiple IM treat-
ments of tetracycline and ampicillin.
The changes in the bacterial counts of individual
bacterial strains in a pig was modeled using estimated
growth parameters from the pharmacodynamic (PD)
model (equation 2) combined with the in vivo drug
profiles, using an ordinary differential equation:
dNi
dt
¼ α ca; ; cbð ÞðNmax−NiNmax Þð
Nmax−ΣNi
Nmax
ÞNi−φNi
ð3Þ
with dNidt : the change in the bacterial counts Ni of strains
i, α(ca, cb): net bacterial growth rate at the combination
of tetracycline concentration ca, and ampicillin concen-
trationcbas given in equation 2,
ð Nmax−NiNmax Þð
Nmax−ΣNi
Nmax
ÞNi : density-dependent growth limi-
tations, which depend on the carrying capacity, Nmax,
and the total bacterial counts summed over all compet-
ing strains in the pig, ΣNi, φNi: bacterial excretion with
outflow rate φ [19].
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Distribution of bacterial strains in pigs was assumed to
be homogeneous. Plasma concentration is often used as a
surrogate for the concentration at the interaction site, and
was therefore used for the bacteria-drug interaction after
an IM injection [20]. The value of the carrying capacity
Nmax was 10
10. The outflow rate φ was taken from
published studies with a value of 0.01 [21, 22]. The model
was initiated with a composition of ten strains with corre-
sponding growth parameters as described in the previous
section. A random selection between 106 and 109 were
allocated as initial values of individual strains. The model
was first run without drugs to attain the dynamic equilib-
rium in the absence of selection pressures [18].
Treatment was introduced once equilibrium was attained
with the inclusion of ten E. coli strains competing in the
intestinal flora of a pig, and the first treatment day defined
as Day 0. In order to assess the growth dynamics post-
treatment, the model was allowed to run for a total of
35 days after the initiation of treatment. This time is
referred to as the end of the weaning period, as treatment
in Danish pig herds is typically initiated during the first two
weeks in the weaning section, where the weaning period
lasts for around 7 weeks. Tetracycline dosage was 20 mg/kg
and ampicillin was 40 mg/kg. Sequential treatments with 2,
3, and 6 cycling frequency were assessed, where a cycling
frequency of 2 refers to the use of each drug for 3 days. To
clarify, cycling frequencies could be written in the following
manner: 2 as (3 + 3), 3 as (2 + 2 + 2), and 6 as (1 + 1 + 1 + 1
+ 1 + 1). These sequential treatments were also assessed in
reverse order, i.e. with tetracycline as the first drug, and
then with ampicillin as the first drug.
The uncertainties in the estimated PD parameters were
assessed by model outputs for 100 repeats, where in each
repeat; parameters were randomly selected from a normal
Fig. 1 Interaction plots of the effect of tetracycline and ampicillin concentrations on bacterial growth. Each box represents one strain,
with the x-axis as tetracycline concentrations and different lines representing ampicillin concentrations
Ahmad et al. BMC Microbiology  (2016) 16:118 Page 4 of 10
distribution of estimated parameters. A simulation envelope
from these repetitions with mean value was reported in the
graphs for single and combination treatments only. The
model was written in R (version 3.0.1 for windows) [14],
and all data were also analyzed and plotted using R.
Results
Combined effect of tetracycline and ampicillin on net
bacterial growth rates of 10 different strains is shown as
an interaction plot (Fig. 1). Different lines in each
subplot depict the ampicillin concentrations whereas
tetracycline concentrations were plotted on x-axis.
Complete horizontal lines represent zero tetracycline
effect, whereas overlapping lines represent zero ampicil-
lin effect on net bacterial growth rate. This occurred due
to high MIC values of strains to tetracycline and
ampicillin (512 μg/ml, 1024 μg/ml etc.), as the maximum
concentration of both drugs used in growth curves was
16 μg/ml. The estimated model parameters, along with
previously estimated parameters (when used as a single
antimicrobial) are given in Table 1. The model used
existing information only for the strains with MIC values
higher than the exposed concentrations (Table 1). There
was no consistent residual structure over the interaction
between the two drugs when analyzed for the different
bacterial strains in the model (Fig. 2), indicating that no
interaction occurred.
Having determined the PD parameters, we proceeded to
the pharmacokinetics of tetracycline and ampicillin. As
described in the methods section, we simulated plasma
concentration-time profiles of the two drugs, based on es-
timated transfer rates (Fig. 3). The two drugs differed in
Fig. 2 Interaction plots of tetracycline and ampicillin showing the relationship between antimicrobial concentration and the residuals from the
fitted combination drug effect model. Each box represents one bacterial strain, with tetracycline concentration on the x-axis and different lines
representing ampicillin concentration
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pharmacokinetic (PK) properties, with ampicillin having a
high absorption and elimination rate with large daily peak
concentration, and tetracycline having a lower elimination
with a smaller peak concentration. The concentration
remained mostly below the MIC values of resistant strains
(MIC > 16) during the treatment period, giving resistant
strains substantial opportunity to outcompete the suscep-
tible ones (Fig. 3).
The estimated growth parameters (Table 1), along with
the PK profiles of the two drugs were used in the mathem-
atical model (equation 3) to simulate the growth dynamics
of the ten competing strains in a pig under single and dual-
antimicrobial treatment of tetracycline and ampicillin
(Fig. 4). The treatment period of 6 days is shown by a
colored window, with treatment start at Day 0. The time
before the treatment window was the period taken by the
model to establish dynamic equilibrium between the ten
competing strains. Dynamic equilibrium is defined as the
growth of multiple strains in a pig, with very small changes
over long periods of time. Antimicrobial treatment disturbs
the dynamic equilibrium of the system, which takes varying
lengths of time to return after the treatment ends. For tetra-
cycline single treatment, three strains resistant to tetracyc-
line (RTSA) and one strain resistant to both tetracycline and
ampicillin (RTRA) had a clear growth advantage (Fig. 4a).
Due to the high level of resistant bacteria at the end of
the tetracycline treatment, it took a long time to regain
the equilibrium. In the case of ampicillin single treat-
ment, the system was also disturbed but not to a large
extent (Fig. 4b), which allowed the system to regain the
equilibrium rapidly. The combination treatment looked
similar to the tetracycline single treatment except double
resistant strains (Fig. 4c, green line) had more growth.
When comparing the fraction of bacterial counts in each
of the four groups, the double resistant group had more
growth advantage than both single treatments (Fig. 5,
red lines). For simplification, corresponding resistant
fractions were quantified at three time points and are
given in Additional file 2: Figure S2.
Sequential treatments (Fig. 6) were found to allow
double resistant strains (red lines) a quicker return to
equilibrium than in combination treatment (Fig. 5c), ir-
respective of cycling frequency. However, within differ-
ent sequential treatments, increased cycling frequency
did not have a major effect on the growth dynamics of
any of the resistant groups (Fig. 6). Moreover, the order
of the two drugs in sequential treatments was only of
consequence when treating with odd cycling frequency
(Fig. 6e) as it resulted in higher tetracycline resistant
strains when tetracycline is used first whereas lower
when ampicillin were used first. For cycling frequency of
2 (Fig. 6a, d) and 6 (Fig. 6c, f ), the growth dynamics of
Fig. 3 Plasma concentration-time profiles of intramuscular tetracycline
(black) and ampicillin (blue) treatments in pigs, based on transfer rates,
estimated from the two-compartmental model. The red line represents
the cut-off value between susceptible and resistant strains to both
tetracycline and ampicillin
Fig. 4 Growth dynamics of ten competing strains before, during and after different antimicrobial treatments. Each line represents a bacterial
strain with different combinations of minimum inhibitory concentration (MIC) values to tetracycline and ampicillin. Treatment is represented by
the color bar from 0 to 6 days
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each resistant group were found to be similar in both se-
quences. Quantifications of resistance at three time
points are shown in Additional file 3.
A broad simulation envelope was reported around the
mean from 100 repetitions, mainly in the tetracycline-
resistant group, which showed large uncertainty in growth
parameters of the tetracycline concentration effect (Fig. 7).
Discussion
Antimicrobial pressure plays a central role in the emer-
gence of antimicrobial-resistant bacteria. In this paper, we
have presented a model evaluating the important factors in
multidrug treatment which are responsible for the emer-
gence of antimicrobial resistance. The model evaluated the
role of combination treatment and sequential treatment in
preventing the growth of resistant strains. Firstly, the model
showed that combination treatment provides an extra
advantage for the double resistant strains to grow and out-
compete the susceptible strains when compared to sequen-
tial treatments. This is in accordance with the guidelines
for improving antibiotic use from the Infectious Disease
Society of America and the Society for Healthcare Epidemi-
ology [23]. Secondly, the model showed that the cycling
frequency in sequential treatments is not very important in
Fig. 5 Fraction of total bacterial counts of strains resistant to tetracycline (black), resistant to ampicillin (blue), resistant to both (red), and
susceptible to both (green) during and after tetracycline, ampicillin and tetracycline + ampicillin intramuscular treatment. Treatment duration is
represented by the color bar
Fig. 6 Fraction of total bacterial counts of strains resistant to tetracycline (black), ampicillin (blue) and both (red) during and after sequential
treatments of tetracycline and ampicillin. a, b, c Treatment with tetracycline is initiated first. d, e, f Treatment with ampicillin is initiated first
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suppressing the growth of resistant strains, whereas the
order of two drugs is influential when using an odd value of
cycling frequency.
Multidrug treatments have been used to treat infections
caused by many important bacterial pathogens [4, 6]. At
the same time, the emergence and growth of antimicrobial
resistance in commensal bacteria is an important concern
[6, 24]. High levels of resistance are generally considered
to be strongly correlated with selection pressures from
antimicrobial use. The use of multiple drug treatments
could boost the growth of resistant bacteria due to large
antimicrobial pressure [6]. Careful investigation of multi-
drug treatments could provide better treatment strategies
that would help to reduce the selection and growth of re-
sistant strains. Many models have been proposed to evalu-
ate the treatment factors that affect the growth of resistant
strains [20, 21, 25–29]. Many of these studies used single
drug exposure, and some used multidrug exposure to as-
sess the effect on the emergence of resistance. Here, we
have used a mathematical model to investigate the effect
of both combination and sequential treatments on the
level of resistance in a scenario of multiple strains, irre-
spective of the infection status.
The model produced realistic changes in antimicrobial
pressure of both tetracycline and ampicillin based on the
transfer rates of the two-compartmental model fitted to
the plasma concentration-time profiles. In contrast to pre-
vious studies, realistic plasma concentration-time profiles
were used in the model (equation 2) to simulate a multi-
drug effect on growth [21, 28]. Moreover, we have
included multiple strains with different antimicrobial
susceptibility profiles in the model, whereas previous stud-
ies evaluated multidrug treatments for a single or small
number of clinical bacterial strains only [5, 28].
When considering the bacterial growth in a pig, one
could argue that high resistance is already established
prior to treatment. Therefore, we have not considered the
role of mutation and conjugation mechanisms in the
growth of resistant strains. As plasma concentrations are
considered an appropriate surrogate marker in most PK
studies and it is difficult to measure drug concentration in
the intestine, we have used plasma concentration as an al-
ternative to drug concentration at the interaction site [30].
Both ampicillin and tetracycline are mainly eliminated by
the kidneys, meaning that a much less amount than the
dose of both drugs reach the intestines from the blood
and could produce different results and must be
accounted for further studies. A single isolated pig was
considered in the model, with excretion of bacteria from
the pig represented by outflow rate (equation 3). The out-
flow rate was kept constant, but it could be varied
dependent on the disease status. The bacterial growth rate
in the absence of a drug (αmax) varied for different strains
and was previously considered to play a role in growth dy-
namics when comparing multidrug treatments. However,
it was assessed by resetting the αmaxto the same value for
all strains in the model and was found to have no apparent
difference (data not shown).
Large uncertainties in PD parameters (reflected in Fig. 7)
were due to a small number of data points between max-
imum and zero growth. These uncertainties could be
reduced by performing in vitro growth curves under nar-
row ranges of antimicrobial concentrations. Limiting
growth factors in the model (equation 2) reflects the in
vivo situation where multiple strains coexist in a pig under
a state of dynamic equilibrium. Our conclusions were
mainly based on simulations of the model (equation 3),
but in future, experimental studies could be performed to
support our model simulations and conclusion.
We examined the multidrug treatments by assessing the
effect on the growth of multiple strains in a pig. The goal
was to compare the efficacy of combination treatment
Fig. 7 Mean and 95 % simulation envelope from 100 repeats of total resistant fraction in each of four groups. Pharmacodynamic parameters in
each repeat were randomly drawn from a normal distribution of estimated parameters
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with both single and sequential treatments in suppressing
the growth of resistant strains. The effect of combination
treatment was similar to the effect of single tetracycline
treatment except there was more growth observed in the
double resistant group (Fig. 5).
Combination treatment with tetracycline and the an-
tagonistic drug ciprofloxacin has previously been shown
to give an advantage of sensitive strains over tetracycline
resistant E. coli [8]. β-lactam drugs and tetracycline are
normally considered antagonistic because tetracycline
works by inhibiting growth, while β-lactam only works
on growing cells. In the current study, we could not find
indications that such an interaction was taking place.
Possible interpretations could be that there was no inter-
action between tetracycline and ampicillin or that the
interaction was dependent upon a complex combination
of MIC and drug concentrations. In other words, the
interaction plot from the current study suggested that
the two drugs with the MIC and concentration distribu-
tions tested had a pharmacodynamic effect independent
of the other drug, when used in combination.
Conclusions
In summary, sequential treatment was more effective in
preventing the growth of resistant strains when compared
to the combination treatment. The cycling frequency did
not play a role in suppressing the growth of resistant
strains, but the specific order of the two antimicrobials did.
Uneven numbers of two drugs (such as ampicillin + tetra-
cycline + ampicillin for 2 days each) in sequential treatment
could be an important consideration when designing multi-
drug treatment strategies. These predictions could be used
to redesign multidrug treatment strategies not only for IM
treatment in pigs, but also for other dosing routes.
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